Differences in monocyte-to-lymphocyte ratio of patients with cervical cancer at dr. Ramelan Central Naval Hospital, Surabaya before and after chemoradiation therapy from January 2020 to July 2023

Background: Cervical cancer is a gynecological malignancy resulting from abnormal and unregulated proliferation of cells, which impairs growth, differentiation, and apoptosis of the cells. Cervical cancer is the second most prevalent disease and is responsible for approximately 10 million deaths in 2020. A number of studies have reported that the monocyte-to-lymphocyte ratio (MLR) may be a useful indicator of the prognosis of patients diagnosed with cervical cancer. Objective: This study aims to determine the differences in monocyte-to-lymphocyte ratio of patients with cervical cancer before and after chemoradiation therapy. Materials and Methods: This study used an analytical observational design with secondary data from 62 patients at dr. Ramelan Central Naval Hospital, Surabaya between January 2020 and July 2023. The sample was taken using a consecutive sampling technique. The variables included patients with stage IIB cervical cancer stage and higher who underwent chemoradiation therapy as well as the monocyte-to-lymphocyte ratio (MLR) of the patients before and after chemoradiation therapy. Results: The results of the Wilcoxon signed-rank test indicated that the therapy had an effect on the MLR of patients with stage IIB cervical cancer and higher, with a p-value of less than 0.001. Conclusion: Significant differences were observed in the MLR of patients with cervical cancer before and after chemoradiation therapy.